Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Kanta FujimotoYui ShibayamaEriko YamaguchiSachiko HonjoAkihiro HamasakiYoshiyuki HamamotoPublished in: Journal of diabetes (2018)
Adding mitiglinide/voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride.